...
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis
【24h】

Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis

机译:女性骨质疏松患者胃肠外唑来膦酸不良反应的研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early. Bisphosphonates remain the mainstay of osteoporosis treatment as they have multimodal action. Oral bisphosphonate therapy has, significant gastrointestinal side effects leading to noncompliance. Of late parenteral Zoledronic Acid is being used as once or twice yearly infusion for the treatment of osteoporosis. Aim: Our article studies the side effect profile and tolerability of parenteral Zoledronic Acid, one of the most potent bisphosphonate used in clinical practice in patients with osteoporosis. Materials and Methods: This study was done in KMC hospitals where 49 patients diagnosed with osteoporosis were included for the study. After obtaining a written informed consent each patient received one infusion of 5 mg Zoledronic Acid as per standard treatment protocol. Patient was monitored for clinical improvement and development of any adverse effects. Conclusion: In our study all subjects reported significant pain relief after infusion of Zoledronic Acid. Zoledronic Acid had very few serious adverse effects that can be prevented through pre-infusion screening, maintaining good hydration and careful patient monitoring. In our population the patients only experienced mild symptoms of pyrexia, arthralgia myalgia and influenza like symptoms which resolved with symptomatic treatment.
机译:简介:骨质疏松症仍然是人群中未得到认可的实体。如果可以及早筛查,诊断和治疗高危人群,可以预防与骨质疏松症相关的骨折。由于双膦酸盐具有多峰作用,因此仍然是骨质疏松症治疗的主要手段。口服双膦酸盐治疗具有明显的胃肠道副作用,导致不依从。晚期肠胃外唑来膦酸被用作每年一次或两次输注以治疗骨质疏松症。目的:我们的文章研究肠胃外唑来膦酸的副作用和耐受性,这是骨质疏松患者临床实践中使用的最有效的双膦酸盐之一。材料和方法:这项研究是在KMC医院进行的,其中包括49位被诊断患有骨质疏松症的患者。在获得书面知情同意后,按照标准治疗方案,每位患者均接受5 mg唑来膦酸输注。监测患者的临床改善和任何不良反应的发展。结论:在我们的研究中,所有受试者均报告了唑来膦酸输注后疼痛明显缓解。唑来膦酸几乎没有严重的不良反应,可以通过输液前筛查,保持良好的水合作用和仔细的患者监测来预防。在我们的人群中,患者仅出现轻度的发热,关节痛,肌痛和流感样症状,这些症状可通过对症治疗来缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号